Min Zhanga,
Kehai Liu*a and
Mingfu Wang
*ab
aCollege of Food Science and Technology, Shanghai Ocean University, 999 Hucheng Ring Road, Shanghai 201306, China. E-mail: khliu@shou.edu.cn
bUniversity Hong Kong, School of Biological Sciences, Pokfulam Road, Hong Kong 999077, China
First published on 22nd October 2019
Programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy has achieved considerable success in various tumours. However, only a fraction of patients benefit from its clinical application, and some patients might be suffer from tumour resistance against PD-1/PD-L1 blockade therapy after the original response. In this review, we summarized the main reasons that caused the low response rate of PD-/PD-L1 blockade therapy: firstly, the off-target of PD-1/PD-L1 blocking agents, which is also the main factor of the side effect of autoimmune disorders; secondly, the insufficient infiltration of T cells in a tumour microenvironment; thirdly, the low immunogenicity of tumor cells; fourth, other immunosuppressive components impairing the therapeutic efficacy of the immunotherapy based on the PD-/PD-L1 blockade, and introducing some updated the delivery system of PD-1/PD-L1 blocking agents and the combination therapy based on PD-1/PD-L1 inhibitors and other therapeutics that can complement and promote each other to achieve improved immune response.
However, PD-1/PD-L1 blockage therapy is not effective for all types of tumours, and still only a relatively small percentage of patients respond to that;4 What's more, some patients might be suffering from tumour resistance against PD-1/PD-L1 blockage therapy after original response.5 There are several possible explanations might be able to help answer and provide guidelines for potential enhancement. First of all, the off-target binding to normal tissues after the administration of PD-1/PD-L1 blocking agents may be one of the reasons why PD-1/PD-L1 blockade therapy shows a low response rate, and that is also the main factor on the side effects like autoimmune disorders. Second, insufficient infiltration of T cells in tumour microenvironment will also lead to a low response rate of PD-1/PD-L1 blockade therapy.6–8 Third, the tumour cells, which survive from immune surveillance and eventually develop into mature tumour tissue, generally have very low immunogenicity. In spite of the dissolve of immune-suppressive signaling on T cells by PD-1/PD-L1 blockade therapy, it is still not easy for the immune system to effectively recognize and kill tumour cells.9–12 Fourthly, the therapeutic efficiency of the immunotherapy is often influenced by the whole immunosuppressive network, while the PD-1/PD-L1 pathway is only one of the most important components of immunosuppressive networks.13,14 In this situation, PD-1/PD-L1 blockade therapy alone might not be able to achieve the evident anti-tumour effect. In addition to above-mentioned, recent studies discovered that some tumour cells could secrete a large proportion of their PD-L1 on exosomes instead of presenting the PD-L1 on their cell surface. Exosomal PD-L1 transmit immunosuppressive signals to draining lymph node to suppresses T cell function and inactivate immune cells at its source,15 and some tumour cells even secret a PD-L1 splicing variants, working as “decoys” of PD-L1 antibody, to induce the tumour resistance to PD-L1 blockade,16 which may also be responsible for the failures of PD-1/PD-L1 blockade therapy.
Thus, it has become a top priority to update the delivery system of PD-1/PD-L1 blocking agents, or develop combination therapy based on PD-1/PD-L1 inhibitors and other therapies that can complement and promote each other to achieve an improved immune response. This review mainly focuses on the recent advances in these two aspects.
Nano-drug delivery system has emerged as a powerful weapon in tumour diagnosis and therapy due to its unique characteristic, such as the protective effect on payload in vivo, improving the targeting delivery, low side effect, etc.23,24 In order to elevate the accumulation and retention of PD-1/PD-L1 inhibitors in the target spots and decrease off-target effects, researchers are trying to incorporate nanotechnology into immunotherapy to enhance the immunotherapeutic responses against tumour cells (Fig. 1).
![]() | ||
Fig. 2 Schematic illustration of the delivery of aPDL1 to the primary-tumor resection site by platelets. Images were reproduced form ref. 30. |
Studies showed that the drug delivery system that directly targeted receptors on the surface of tumour cells, did not seem to work as expected. Most nanoparticles get into tumour tissues relying on enhanced permeability and retention effect, and their efficacy also has been highly pronounced in preclinical models of solid tumours equipped with leaky vasculature, however, which may not suitable for the tumours that develop over the course of years rather than days. It is noticeable that immune cells could migrate actively alone the chemokine gradients to sites of inflammation, like tumours. Instead of targeting tumours directly, Schmid et al.32 attempted to develop a PD-1 antibody-target nanoparticles that bind to CD8+ cells circulating in the blood or in the lymphoid tissues and tumours of mice, by means of which, immunomodulatory compounds and anti-PD-1 can be effectively delivered into tumour site better than systemic administration of free drug (Fig. 3).
![]() | ||
Fig. 3 Schematic illustration of the preparation of PD-1 antibody-target nanoparticles, and its trafficking mechanism to the target spot. Images were partly reproduced form ref. 32. |
In addition to the direct target delivery of anti-PD-1/PD-L1 inhibitors aforementioned, researchers also tried to explore innovative strategies that aimed at transporting therapeutic proteins on a genetic level to accomplish the tumour-specific delivery of PD-1/PD-L1 inhibitors. Adeno-associated viral (AAV) vectors are one of the most promising vehicles for in vivo gene delivery. Reul et al.33 constructed a tumour-target Her2-AAV used as a vehicle for the coding sequence of an scFv-Fc fusion protein delivery that directed against mouse PD-1. Transduction of Her2/neu+ RENCA cells revealed that AAV-encoded aPD-1 could be readily detected and Her2-AAV also could mediate specific gene delivery into tumour lesions via intravenous administration in BALB/c mice bearing subcutaneous RENCA-Her2/neu tumours. Not only that, but AAV could also be levered to mediate extracellular domain of PD-1 (sPD-1) expression and disrupt the negative immunoregulatory signals provided by PD-1/PD-L1 pathway. The experimental results suggested that the expressed sPD-1 could block the PD-1/PD-L1interaction, and local gene transfer of sPD-1 in tumour site could potently inhibit tumour growth and prolong the survival of mice. These all provide proof of concept that tumour-targeted vectors can be used for the targeted delivery of PD-1/PD-L1 inhibitors on a genetic level to the tumour site.
Based on the above theory, some researchers wondered whether this goal could be accomplished by means of retroviral siRNA delivery. The experimental results indicated that effective target siRNA sequences delivery reduced the surface PD-1 expression, which led to activated T-cell immune functions in response to PD-L1 positive melanoma cells.36 Some synthetic polymers, such as cyclodextrin-based polycations, polyethylenimine (PEI) and polyphosphates also have been used for siRNA delivery.37,38 After a series of functional modifications on these non-viral vector materials, it can successfully deliver siRNA to the target site against the complex in vivo environment and effectively release it for anti-tumour treatment. For example, the application of the adoptive T cell immunotherapy in tumour treatment is impressive. However, it also suffers from various immunosuppressive mechanisms exerted by tumour cells as well as host immune cells in the tumour microenvironment, including the PD-1/PD-L1 pathway. Hence, Teo et al. attempted to delivery PD-L1 siRNA utilizing various folic acid (FA)-functionalized PEI polymers to SKOV-3-Luc EOC cells, and studied the sensitization of the EOC cells to immunotherapy.39 The results indicated that all polymers induced 40% to 50% PD-L1 protein knockdown, and importantly, SKOV-3-Luc cells treated with the polymer/PD-L1 siRNA complexes showed up to twofold more sensitive to T cell immune response in comparison with scrambled siRNA treated controls.
These findings demonstrated that PD-L1 knockdown in PD-L1 positive tumour cells, via PD-L1 siRNA targeting delivery, are able to block the PD-1/PD-L1 pathway and enhance the anti-tumour immune response. More importantly, the PD-1/PD-L1 blocking by PD-L1 knockdown might be able to reduce the immune-related side effects and bypass the failure of PD-1/PD-L1 inhibitors caused by exosomal PD-L1 and “decoys” of PD-L1 antibody secreted on some tumour cells, as we mentioned before.
Tumour cell lysate, representing a spectrum of tumour-associated antigens, could be facilely processed into vaccines without further sequencing or antigen synthesis.52 However, it has been shown that tumour cell lysate based vaccination only induces weak tumour-specific T cells responses, and simulates slender therapeutic efficacy.53 To address this problem, Ochyl et al.54 reported a method for generating tumour cell lysate based PEGylated vaccine nanoparticles (PEG-NPs). This nano-vesicles PEG-NPs not only solved the problem for its own instability in vivo, but also improved the delivery efficiency of tumour vaccine. Results demonstrated that PEG-NPs vaccination elicited more antigen-specific T cell responses than standard freeze-thawed lysate vaccination by 3.7 times in tumour-bearing mice. Importantly, when combined with a PD-1 antibody, PEG-NP vaccination triggered 4.2 times stronger antigen-specific T cell responses, and resulted in 63% of tumour regression of tumour-bearing animals, while FT lysate and PD-1 antibody combination treatment displayed only 13% response rate. Besides, PEG-NP vaccination combined with PD-1 antibody immunotherapy could protect all survivors from further tumour cell re-challenge.
There were also documentaries demonstrated that whole tumour cell vaccines exhibited modest efficacy due to the similar antigens spectrum pattern between tumour cells and normal cells.55 Recent advances have examined closely the immunogenicity of various subcellular compartments of tumour cells, including cells membranes, cytosol, and nucleus, and the results showed that tumour-associated antigens were located on the tumour cells membranes in several types of tumour, which could be exploited as personalized therapeutic anti-tumour vaccines materials to irritate adaptive immune response.56 Therefore, the “artificial necroptotic cancer cell”, named αHSP70p-CM-CaP, was developed to deliver tumour membrane proteins plus additional boosting adjuvants.57 After the administration of αHSP70p-CM-CaP, effective lymph node trafficking and strong T cells response were detected in mice. Especially, when combined with a PD-1 antibody, αHSP70p-CM-CaP vaccination could result in the killing of tumour cells and mediate tumour regression in B16OVA melanoma mice.
In addition to these tumour vaccines, epigenetic modulators including hypomethylation agents (HMAs), were also used to enhance the immunogenicity of tumour cells via inducing tumour-associated antigen expression. Moreover, HMAs has been proved to relieve immunosuppressive tumour microenvironment by reducing the number of myeloid-derived suppressor cells (MDSCs), and not only that, HMAs also could mediate the upregulation of immunosuppressive ligands including PD-L1/PD-L2, increasing the sensitivity of tumours to PD-1/PD-L1 blockade therapy.58 The HMAs and PD-1 antibody combination treatment showed enhanced the immunogenicity of tumour cell, and reversed immunosuppressive tumour microenvironment to some extent, leading to the tumour regression and prolonged the survival time of mice.
Based on the above data, we could find that the personalized therapeutic anti-tumour vaccines eliciting endogenous cytotoxic T cells responses against tumour cells offer a promising strategy in working synergistically with PD-1/PD-L1 blockade therapy.
Chemotherapy is one of the three widely accepted conventional methods for tumour treatment that obtain anti-tumour effects by killing tumour cells using cytotoxic drugs.60 However, due to the poor selectivity, chemotherapy may cause a certain degree of toxic effects on the immune system. The traditional concept holds that there is an antagonistic effect between chemotherapy and immunotherapy, and these two treatment methods are difficult to use together. The situation has changed with an accumulation of data on the synergistic therapeutic effect obtained by a combination of immunotherapy and chemotherapy in multiple tumour treatments. Accumulating evidence suggests that chemotherapeutics induced cell death could produce plentiful of tumour debris in situ and mediate a large quantity of tumour-associated antigens releases, such as calreticulin (CRT), heat shock proteins (HSPs), high-mobility group box 1 protein (HMGB1) and adenosine triphosphate (ATP), which leads to the activation of tumour-specific cognate immune responses.61 This process is known as immunogenic cell death (ICD).62 In principle, ICD could establish an unbiased tumour antigen repertoire that covers all types of tumour antigens, and concomitantly trigger broad specific antitumour immunity. For example, Li et al.63 tried to subvert the GBM immunosuppressive microenvironment by DC-mediated delivery of doxorubicin–polyglycerol–nanodiamond composites (Nano-Dox). In vitro study on human cell models showed that Nano-DOX treated GC exhibited profuse DAMPs emission and antigen release.
In addition, chemotherapy could sensibilize tumour cells to cytotoxic T lymphocyte in vivo. For instance, paclitaxel (PTX), doxorubicin (DOX) and cisplatin were shown to increase the sensitivity of tumour cells to cytotoxic T lymphocytes specific killing effect due to the upregulation of mannose-6-phosphate receptors (M6PR) on cells and increase of the cells permeability to granzyme-B (GrzB) secreted by cytotoxic T lymphocytes.64 What's more, chemotherapy could also relieve the immunosuppression of tumour microenvironment by eliminating immunosuppressive cells, such as regulatory cells (tregs) and MDSCs.65 Immunotherapy, in turn, also could make a positive contribution to the efficiency of chemotherapy for tumour treatment (Fig. 5). For instance, immunotherapy performs an important role in rebuilding the human immune system and maintaining the immune balance of patients, and it also could effectively solve the patient's insensitivity to chemotherapy by enhancing the anti-tumour immune response, which can not only ensure the efficacy of chemotherapy but also improve the human immunity and reduce the toxic effects of chemotherapeutics.
As mentioned above, under certain conditions, chemotherapeutics could promote anti-tumour immune responses in many aspects. However, indeed, systemic chemotherapy would damage the bone marrow and subsequently influence the number and activation state of resident immune cells,66 evoking concerns for potential antagonistic interactions between systemic chemotherapy and immunotherapy. One study showed that local chemotherapy could reduce the risk of immune cells damages and promote anti-tumour immune response, and when combined with anti-PD-1, it exhibited enhanced anti-tumour immune response and prolonged survival in glioblastoma. Besides, local chemotherapy-treated mice displayed increased infiltration of tumour-associated dendritic cells and proliferation of antigen-specific T effector cells, while systemic chemotherapy brought about systemic and intratumoural lymphodepletion, accompanied with decreased immune memory in long-term survivors. More importantly, adoptive transfer of CD8+ cells from local chemotherapy-treated mice partly rescued systemic chemotherapy-treated mice in rechallenge experiments.
In order to achieve improved anti-tumour efficiency and reduced side effects, Wang et al.67 engineered a therapeutic scaffold, which consisted of reactive oxygen species (ROS) degradable hydrogel that could release therapeutics in a programmed manner within the tumour microenvironment (TME) containing abundant ROS, aiming at achieving local release of gemcitabine (GEM) and anti-PD-L1 antibody (aPDL1). The experimental results showed that the aPDL1-GEM scaffold could elicit an immunogenic tumour phenotype and enhance an immune-mediated tumour regression, accompanied by prevention of tumour recurrence after primary surgical excision.
Based on above, we could find that the PD-1/PD-L1 blockade therapy combined with chemotherapy is expected to solve the problem of low response to PD-1/PD-L1 blocking agents caused by low tumour immunogenicity, and provide mutual promoted effects for tumour treatment at the same time. In addition to these chemotherapeutics, there are other tumour therapies that also could induce tumour ICD, including ionizing irradiation, photodynamic therapy, cardiac glycosides, cyclophosphamide, shikonin and oncolytic viruses. These tumour treatments also could be considered as a potential adjunctive treatment.
For example, scientists realized that the limited efficiency of PD-1/PD-L1 blockade therapy might be on account of costimulation deficiency in tumour microenvironment in the setting, at which the APCs encounter the tumour cells and T-cell. To address this issue, Wang et al.69 attempted to introduce the potent immunostimulatory effects of CpG ODNs into the checkpoint inhibition therapy and developed a novel stimuli-responsive delivery vector to realize the controlled release of anti-PD-1 antibody and CpG ODNs at tumour sites and exert synergistic antitumour activity. This innovative CpG ODNs-based drug delivery system not only served as a delivery intermediary for anti-PD-1 antibody but also could enhance anti-tumour efficiency after being fragmented. And the studies demonstrated that the bioresponsive controlled release of PD-1 antibody and CpG ODNs exerted more effective anti-tumour responses than either of them.
In addition, CpG-ODNs were also used as components of nanovaccine for tumour immunotherapy. Following CpG ODNs-based nanovaccine administration, the immunogenic antigen materials and CpG ODNs could be effectively co-delivered to APCs, boosting anti-tumour immunity. When combined with the anti-PD-1 antibody, CpG ODNs-based nanovaccine could mediate effective tumour regression in vivo.57,70 Altogether, these data demonstrated proof-of-concept evidence that CpG ODNs used as boosting adjuvants for triggering innate immune system also provide a potential strategy in working synergistically with PD-1/PD-L1 blockade therapy.
Type I interferons (IFNs) could inhibit tumour growth by promoting DC cross-priming to (re-)activate T cell,74 while the expression of IFNs in the tumour tissue is limited or restrained. In addition, although local delivery of IFNs can restore antigen presentation, it also upregulates the expression of PD-L1 and inhibits the following T cells activation. Liang et al.75 developed a conjugate based on anti-PD-L1 antibody and IFNα to create feedforward responses. It was shown that this conjugates could overcome both IFNs and PD-1/PD-L1 blockade therapy resistance and achieve a synergistic anti-tumour effect with the least side effects. Intriguingly, IFNα-mediated upregulation of PD-L1 increased the targeting distribution of the fusion protein. The antibody-cytokine fusions have been widely studied to conduct cytokine-based therapies for tumour. However, the size of these adducts severely decreased the tissue penetration and the subsequent concentration of cytokines at the right location. Alternatively, the heavy chain-only antibody fragments anti-PD-L1 antibody derived from alpaca was selected to construct antibody-cytokine fusion.76 Targeted delivery of antibody-cytokines conjugates in this manner significantly inhibited tumour growth.
Tumour or tumour-associated immune cells could also secrets immunosuppressive molecules to induce immune tolerance in the tumour microenvironment, such as indoleamine 2, 3-dioxygenase (IDO) and TGFβ. IDO, an important negative feedback protein overexpressed by tumour and IDO+ DCs, involves in the cell cycle arrest and apoptosis of effector T cells, and increasing the production of Tregs in tumour.77,78 In order to achieve better anti-tumour effect, researchers attempted to encapsulate IDO inhibitor into anti-PD-1 antibody delivery system for synergistically blocking immune tolerance signals in the tumour microenvironment, and exhibited significant tumour regression.79 Except for the directly delivery of immunosuppressive molecules inhibitor, it has been validated that intratumoural administration of mRNA encoding a fusion protein of the ectodomain of TGFβ receptor II and interferon-β showed therapeutic potential,80 and the anti-tumour efficacy could be improved when combined with blockade of PD-1/PD-L1 interactions. The ectonucleotidases CD39 and CD73, acting in unison to transform extracellular immune-stimulating ATP into adenosine, are two new drug targets. Hence, the inhibition of CD39 and CD73 may be able to promote the subversion of tumour immunosuppressive microenvironment and enhance the anti-tumour immune response.81
Macrophages play a crucial role in regulating tumour development and metastasis. Extensive researches suggested that tumours could constantly recruit M2 tumour associated macrophages (TAMs) into tumour tissue, and the TAMs density have a positive correlation with poor prognosis in various human tumours.82 Therefore, many scientists tried to set about manipulating the TAMs functions to improve the efficacy of immunotherapies, and also achieved certain positive effects.83,84
The tumour stroma is also one of the most important components of the immunosuppressive tumour microenvironment. Its highly fibrotic construction and structurally abnormal blood vessels pose a powerful physical barrier to CTL infiltration, leading to poor efficiency of PD-1/PD-L1 blockade therapy. A large portion of tumours has been examined to comprise high levels of hyaluronan (HA), which was an important component of the extracellular matrix (ECM) of tumours.85 Thus, in order to improve the intratumoural delivery of therapeutic molecules and enhance the CTL infiltration in tumour tissues, hyaluronidase (HAase) was used to digest the overexpressed HA, and achieved a positive effect.86 However, this approach is only suitable for patients with high levels of HA. For another, tumour vascular normalization has been gradually accepted as promising strategy for promoting drug delivery and encouraging immune cells infiltration.87 Sonic hedgehog (SHH) is generally upregulated, and plays an important role in the formation of tumour stroma in the majority of pancreatic ductal adenocarcinoma.88 Zhao et al.89 developed a nano-formulation of cyclopamine (CPA), a SHH inhibitor, used for tumour treatment. The preclinical results showed that the CPA nano-formulation increased tumour infiltration by CTLs and improved the susceptibility to anti-PD-1 antibody therapy in an orthotopic murine pancreatic ductal adenocarcinoma model. The lysophosphatidic acid receptor 4 (LPA4) is another therapeutic target of the stroma-modulating agent, and the activation of LPA4 induces fine vascular network formation in brain tumours. LPA treatment improved the delivery of anti-PD-1 antibody and lymphocyte infiltration into brain tumour tissues, resulting in the enhanced anti-tumour effect of PD-1 blockade therapy.90 These data demonstrated that co-delivery of a stroma-modulating agent and PD-1/PD-L1 pathway inhibitors is a promising approach to enhance the response rate of PD-1/PD-L1 blockade therapy.
One more thing we can't ignore is that tumours are the living, dynamic changing organisms. Just as with the other organism, under the threat of adverse factors they are inclined to avoid danger or instinctively induce a series of resistance mechanisms to protect themselves. The most glaring examples are a range of drug-resistance mechanisms of tumours against chemotherapies. Recently, drug resistance phenomenon has also been observed in immunotherapy for tumours treatment. For example, PD-1 blockade therapy has been found to promote the expression of pro-tumour inflammatory cytokines that potentially counteract the anti-tumour effects of PD-1 blockade,92,93 and the anti-PD-L1 antibody “decoys” mechanism disables the anti-PD-L1 antibody blockade therapy;16 Most astonishingly, when the chimeric antigen receptors (CARs) T cells were used for tumour treatment, CARs could provoke reversible antigen loss via trogocytosis, and the target antigen could be transferred to T cells through this active process, thereby reducing target antigen density on tumour cells and inhibiting T cell activity by initiating fratricide T cell killing and promoting T cell exhaustion.94 Based on these understandings, we speculate that the future direction might lie in the combined therapy based on PD-1/PD-L1 blockade and personalized tumour vaccines. The activation of a specific and sustained anti-tumour immune response, rather than blindly suppressing the tumour using brute-force, is of great significance in tumour regression.
ICB | Immune checkpoint therapy |
PD-1 | Programmed death-1 |
PD-L1 | Programmed death-ligand 1 |
AAV | Adeno-associated viral |
sPD-1 | Extracellular domain of PD-1 |
siRNA | Silencing RNA |
RNAi | RNA interference |
PEI | Polyethylenimine |
FA | Folic acid |
PEG-NPs | PEGylated vaccine nanoparticles |
HMAs | Hypomethylation agents |
MDSCs | Myeloid-derived suppressor cells |
CRT | Calreticulin |
HSPs | Heat shock proteins |
HMGB1 | High-mobility group box 1 protein |
ATP | Adenosine triphosphate |
ICD | Immunogenic cell death |
Nano-Dox | Doxorubicin–polyglycerol–nanodiamond composites |
PTX | Paclitaxel |
DOX | Doxorubicin |
M6PR | Mannose-6-phosphate receptors |
GrzB | Granzyme-B |
Tregs | Regulatory cells |
ROS | Reactive oxygen species |
TME | Tumour microenvironment |
GEM | Gemcitabine |
aPDL1 | Anti-PD-L1 antibody |
CpG ODNs | CpG-oligodeoxynucleotides |
APCs | Antigen-presenting cells |
IL-6 | Interleukin-6 |
TNF | Tumour necrosis factor |
IL-12 | Interleukin-12 |
IFNs | Type I interferons |
IDO | Indoleamine 2, 3-dioxygenase |
TAMs | Tumour associated macrophages |
HA | Hyaluronan |
ECM | Extracellular matrix |
HAase | Hyaluronidase |
SHH | Sonic hedgehog |
CPA | Cyclopamine |
LPA4 | Lysophosphatidic acid receptor 4 |
CARs | Chimeric antigen receptors |
This journal is © The Royal Society of Chemistry 2019 |